Virus therapy with immunotherapy for recurrent brain tumor
Part of Cancer clinical trials.
This trial tests a new treatment that combines a specially designed virus to attack tumor cells with an immunotherapy drug to help the immune system fight the cancer. It is for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a high-grade glioma that has returned or progressed after standard treatment.
- You have at least one measurable tumor (at least 10 mm in size).
- You are able to have a device placed in your head for direct tumor treatment.
- You are generally in good health (able to care for yourself, with a KPS score of 50 or more).
- You do not have active infections, severe heart problems, or other serious conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
This trial tests a modified virus that may help treat a type of brain cancer called high-grade glioma. It is for patients who have not yet had any treatment for their tumor.
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
This Phase 1 trial tests a lab-made cancer virus (Ad-TD-nsIL12) in children with DIPG whose tumor keeps growing after standard treatment. It mainly focuses on safety and how the treatment works, and it may help shrink or control the tumor by stimulating the immune system.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.